Stimulation of PGE2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following β‐amyloid exposure
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is associated with gliosis, neuroinflammation and higher levels of prostaglandins. Conflicting roles for cyclooxygenases and prostaglandins in the etiopathology of AD have been reported. We hypothesized that PGE 2 signaling through EP2 and EP4 G‐protein‐coupled receptors could protect against amyloid β‐peptide (Aβ) neurotoxicity by increasing the cAMP signaling cascade. Using primary neuronal cultures, we investigated the presence of EP receptors (EP1–4) and the action of PGE 2 and EP receptor agonists on neuronal susceptibility to Aβ 1−42 toxicity. Low concentrations (1 µ m) of PGE 2, butaprost (EP2 agonist), and 1‐hydroxy‐PGE 1 (EP4/EP3 agonist) were neuroprotective against Aβ 1−42 toxicity, while sulprostone (EP3/EP1 agonist) at similar doses had no detectable effects. EP2 and EP4 receptor‐mediated neuroprotection would involve changes in cAMP levels, as both EP2 and EP4 agonists increased intracellular cAMP concentration by approximately doubling basal levels, and both exhibited neuroprotective actions against Aβ‐induced toxicity. The protein kinase A (PKA) inhibitor RpcAMPS significantly attenuated the neuroprotection by butaprost, but not that by 1‐hydroxy‐PGE 1, implying differences between EP2 and EP4 receptor protective mechanisms. Additionally, the increase in reactive oxygen species generated following exposure to Aβ was reduced by stimulation of both EP2 and EP4 receptors. Together, these results indicate that PGE 2 can protect neurons against Aβ toxicity by acting on given receptors and stimulating a cascade of intracellular events, including the cAMP–PKA pathway. We propose that development and testing of specific PGE 2 receptor agonists downstream of cyclooxygenase could lead to therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123 · cited 1×
“Ab1)42 self-associates into oligomers, protofibrils and fibrils that are toxic to neuronal cells in vitro and in vivo (Doré et al., 1997; Hsia et al., 1999; Chromy et al., 2003; Gong et al., 2003; Oddo et al., 2003; Selkoe & Schenk, 2003; Echeverria et al., 2004a,b).”
BackgroundGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 1×
“Ab1)42 self-associates into oligomers, protofibrils and fibrils that are toxic to neuronal cells in vitro and in vivo (Doré et al., 1997; Hsia et al., 1999; Chromy et al., 2003; Gong et al., 2003; Oddo et al., 2003; Selkoe & Schenk, 2003; Echeverria et al., 2004a,b).”
BackgroundProstanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011 · cited 4×
“The activation of EP3 receptors leads to a decrease in cAMP levels via inhibition of adenylate cyclase and an increase in calcium levels via Gq protein stimulation (Breyer et al., 2001).”
BackgroundInfluentialAmyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 1×
“Ab1)42 self-associates into oligomers, protofibrils and fibrils that are toxic to neuronal cells in vitro and in vivo (Doré et al., 1997; Hsia et al., 1999; Chromy et al., 2003; Gong et al., 2003; Oddo et al., 2003; Selkoe & Schenk, 2003; Echeverria et al., 2004a,b).”
BackgroundDisruption of CREB function in brain leads to neurodegeneration
Mantamadiotis, T., Lemberger, T., Bleckmann, S. C., Kern, H., Kretz, O., Villalba, A. M., Tronche, F., Kellendonk, C., Gau, D., Kapfhammer, J., et al. (2002) · Nature Genetics · doi:10.1038/ng882 · Cited by 684 · cited 2×
“In addition, the transcription factor CREB, a target of PKA activity, has a confirmed role in promoting neuronal survival (Mantamadiotis et al., 2002).”
BackgroundSelf-Assembly of Aβ 1 - 42 into Globular Neurotoxins
Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., et al. (2003) · Biochemistry · doi:10.1021/bi030029q · Cited by 522 · cited 1×
“Ab1)42 self-associates into oligomers, protofibrils and fibrils that are toxic to neuronal cells in vitro and in vivo (Doré et al., 1997; Hsia et al., 1999; Chromy et al., 2003; Gong et al., 2003; Oddo et al., 2003; Selkoe & Schenk, 2003; Echeverria et al., 2004a,b).”
BackgroundGong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 2×
“nervous system, improved synaptic and cognitive functions in a mouse AD model (Gong et al., 2004).”
BackgroundResult
Cited by
Woodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
Sirt1 activation protects the mouse renal medulla from oxidative injury
He, W., Wang, Y., Zhang, M.-Z., You, L., Davis, L. S., Fan, H., Yang, H.-C., Fogo, A. B., Zent, R., Harris, R. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41563 · Cited by 317
Transcription factor Sp1 dysregulation in Alzheimer's disease
Citron, B. A., Dennis, J. S., Zeitlin, R. S., & Echeverria, V. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21695 · Cited by 116
“Phosphorylation/dephosphorylation regulation associated with this pathway has been described elsewhere (Suo et al., 2004; Echeverria et al., 2005).”
BackgroundAnti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Cimino, P. J., Sokal, I., Leverenz, J., Fukui, Y., & Montine, T. J. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090443 · Cited by 49
Metadata
- Authors
- Echeverria, V., Clerman, A., & Doré, S.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2005-11
- Volume
- 22
- Issue
- 9
- Pages
- 2199-2206
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2006819998
- Cited by
- 119
- References
- 12
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stimulation of PGE2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following β‐amyloid exposure. https://app.cochat.ai/papers/10.1111/j.1460-9568.2005.04427.x
- The paper
- Echeverria, V., Clerman, A., & Doré, S. (2005). Stimulation of PGE2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following β‐amyloid exposure. European Journal of Neuroscience. https://doi.org/10.1111/j.1460-9568.2005.04427.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.